NCT04261439 2025-05-06
A Phase I/Ib Study of NIZ985 Alone and in Combination With Spartalizumab
Novartis
Phase 1 Terminated
Novartis
Intensity Therapeutics, Inc.
Chinese PLA General Hospital
Symphogen A/S
Novartis
Novartis
Novartis
Chinese PLA General Hospital